Wutah bathi EPS kuartalan polyrizon-biotech.com (PLRZ)

The quarterly EPS trend demonstrates the potential of Polyrizon Ltd (PLRZ) and its Trap and Protect technology, which creates a barrier against viruses and allergens. However, the speculative nature of early-stage development and a liquidity deficit create a risk of capital dilution, with the current parameter equal to -7.00. A critical dependence on third-party CROs and a lack of in-house capacity leave the business entirely reliant on external outsourcing.

This indicator measures the dynamics of net profit per share by calculating the percentage deviation of the current quarterly EPS from the same period last year to assess business scaling rates. By analyzing the quarterly EPS growth rate, a Polyrizon Ltd (PLRZ) investor can promptly track the impact of geopolitical instability in Israel on bio-laboratory profitability and the resilience of component supply chains.